«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年05期

页码:

408-411，428

栏目:

基础医学

出版日期:

2020-09-20

文章信息/Info

Title:

Nrf2 promotes the migration and invasion in hepatocellular carcinoma

文章编号:

1006-8147(2020)05-0408-05

作者:

张宁; 赵秀兰; 李勇莉; 董学易; 赵楠; 刘铁菊

（天津医科大学基础医学院病理学教研室，天津 300070）

Author(s):

ZHANG Ning;  ZHAO Xiu-lan;  LI Yong-li;  DONG Xue-yi;  ZHAO Nan;  LIU Tie-ju

（Department of Pathology, College of Basic Medicine, Tianjin Medical University, Tianjin 300070, China）

关键词:

肝细胞肝癌; MMP; Nrf2; 迁移; 侵袭; 预后

Keywords:

hepatocellular carcinoma;  MMP;  Nrf2;  migration;  invasion;  prognosis

分类号:

R735.7

DOI:

-

文献标志码:

A

摘要:

目的：探讨核转录因子Nrf2对肝癌细胞迁移及侵袭能力的影响。方法：将Nrf2过表达质粒通过慢病毒包装后分别转染至肝癌细胞系HCC-LM3及Bel-7402中，通过划痕实验、Transwell侵袭实验观 察Nrf2对肝癌细胞迁移运动及侵袭能力的影响，使用Western印迹法检测转染后的HCC-LM3及Bel-7402肝癌细胞中基质金属蛋白酶2（MMP2）与基质金属蛋白酶9（MMP9）表达情况，通过收集网络数据库 GEPIA中相关临床资料信息分析Nrf2对肝癌患者生存时间的影响。结果：在肝癌细胞系HCC-LM3与Bel-7402中过表达Nrf2，其迁移侵袭能力均明显增强。此外发现过表达Nrf2的HCC-LM3肝癌细胞中MMP2及 MMP9表达均增加（t=2.879、5.582, 均P <0.05）；Bel-7402肝癌细胞转染Nrf2过表达质粒后，其MMP2及MMP9表达也相对增加（t=3.756、2.968, 均P <0.05）。高表达Nrf2的肝癌患者生存时间短于低表 达Nrf2的肝癌患者（Logrank P=0.042）。结论：肝癌细胞Nrf2高表达可能通过增加MMP2及MMP9的表达，进而促进肝癌细胞迁移及侵袭能力，并且Nrf2高表达与肝癌患者的不良预后有关。

Abstract:

Objective: To study the effect of Nrf2 on the migration and invasion in hepatocellular carcinoma. Methods: HCC-LM3 cells and Bel-7402 cells were transfected with the Nrf2 overexpression plasmid packaged by lentivirus to induce the exogenous expression of Nrf2. The wound healing assay and Transwell migration assay were used to determine the effect of Nrf2 on the invasion and migration in hepatocellular carcinoma. The expression of matrix metalloproteinase 2(MMP2) and matrix metalloproteinase 9(MMP9) was analyzed by Western blot and compared with that in the control. The effect of Nrf2 on the survival time of patients in liver cancer was analyzed through collecting relevant clinic information in GEPIA. Results: After transfection, HCC-LM3 cells and Bel-7402 cells with the Nrf2 overexpression plasmid showed enhanced invasion and migration. In addition, it was found that the expression of MMP2 and MMP9 in HCC-LM3 cells overexpressing Nrf2 were increased(t=2.879, 5.582, all P<0.05); meanwhile, the expression of MMP2 and MMP9 in Bel-7402 cells transfected with the Nrf2 overexpression plasmid were also increased(t=3.756, 2.968, all P<0.05). The survival time of patients in liver cancer with the high Nrf2 expression was shorter than that of patients with the low Nrf2 expression（Logrank P=0.042）. Conclusion: Nrf2 might promote the migration and invasion in hepatocellular carcinoma by increasing MMP2 and MMP9 expression. And the expression of Nrf2 is related to the poor prognosis of patients in liver cancer.

参考文献/References:

[1] Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma[J]. Exp Clin Cancer Res, 2019, 38(1) :447
[2] Couri T, Pillai A. Goals and targets for personalized therapy for HCC[J]. Hepatol Int, 2019, 13(2) :125
[3] Song R, Song H, Liang Y, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis[J]. Hepatology, 2014, 60(5) :1659
[4] Li Q, Xing S, Chen Y, et al. Reasonably activating Nrf2: a long-term, effective and controllable strategy for neurodegenerative diseases[J]. Eur J Med Chem, 2019:111862
[5] Pompili S, Sferra R, Gaudio E, et al. Can Nrf2 modulate the development of intestinal fibrosis and cancer in inflammatory bowel disease[J]. Int J Mol Sci, 2019, 20(16): 4061
[6] Zimta A A, Cenariu D, Irimie A, et al. The role of Nrf2 activity in cancer development and progression[J]. Cancers, 2019, 11(11) :1755
[7] Wu S, Lu H, Bai Y. Nrf2 in cancers: a double-edged sword[J]. Cancer Med, 2019, 8(5) :2252
[8] 朱笑生,刘文超. 原发性肝癌全球流行情况和危险因素的新进展[J]. 现代肿瘤医学, 2018, 248(14) :163
[9] Sarveazad A, Agah S, Babahajian A, et al. Predictors of 5 year survival rate in hepatocellular carcinoma patients[J]. J Res Med Sci, 2019, 24:86
[10] Han T S, Ban H S, Hur K, et al. The epigenetic regulation of HCC metastasis[J]. Int J Mol Sci, 2018, 19(12) :3978
[11] Cloer E W, Goldfarb D, Schrank T P, et al. NRF2 activation in cancer: from DNA to protein[J]. Cancer Res, 2019, 79(5) :889
[12] Jin M, Wang J, Ji X, et al. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1) :136
[13] Zhang C, Wang H J, Bao Q C, et al. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction[J]. Oncotarget, 2016, 7(45) :73593
[14] Zhao Q, Mao A, Guo R, et al. Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch axis[J]. Oncotarget, 2017, 8(22) :36603
[15] Huang Y, Mao Y, Li H, et al. Knockdown of Nrf2 inhibits angiogenesis by downregulating VEGF expression through PI3K/Akt signaling pathway in cerebral microvascular endothelial cells under hypoxic conditions[J]. Biochem Cell Biol, 2018, 96(4) :475
[16] Wei Y, Liu D, Jin X, et al. PA-MSHA inhibits the growth of doxorubicin-resistant MCF/ADR human breast cancer cells by downregulating Nrf2/p62[J]. Cancer Med, 2016, 5(12) :3520
[17] Chen J, Yu Y, Ji T, et al. Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma[J]. Cancer Med, 2016, 5(10) :2678
[18] Yu S, Cheng C, Wang J, et al. Loss of Beclin1 expression and Nrf2 overexpression are associated with poor survival of patients with non-small cell lung cancer[J]. Anticancer Agents Med Chem, 2018, 18(12) :1680
[19] Ryoo I, Choi B, Ku S K, et al. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: implications for cancer stem cell resistance[J]. Redox Biol, 2018, 17: 246
[20] Deryugina E I, Quigley J P. Matrix metalloproteinases and tumor metastasis[J]. Cancer Metastasis Rev, 2006, 25(1) :9
[21] Kalhori V, Rnquist K. MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells[J]. Mol Cell Endocrinol, 2015, 404:113
[22] Dou C Y, Cao C J, Wang Z, et al. EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity[J]. Oncol Rep, 2016, 35(6): 3489
[23] Jacob A, Jing J, Lee J, et al. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells[J]. J Cell Sci, 2013, 126(20): 4647
[24] Kondratiev S, Gnepp D R, Yakirevich E, et al. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas[J]. Hum Pathol, 2008, 39(3) :337
[25] Wang L, Wang Q, Li H L, et al. Expression of miR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma - relationship with prognosis[J]. Asian Pac J Cancer Prev, 2013, 14(3): 2113
[26] Liu J, Ping W, Zu Y, et al. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2014, 7(9): 6040
[27] Cernigliaro C, D’Anneo A, Carlisi D, et al. Ethanol-mediated stress promotes autophagic survival and aggressiveness of colon cancer cells via activation of nrf2/ho-1 pathway[J]. Cancers, 2019, 11(4): 505
[28] Zhang M, Zhang C, Zhang L, et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma[J]. BMC Cancer, 2015, 15(1): 531
[29] Pan H, Wang H, Zhu L, et al. The role of Nrf2 in migration and invasion of human glioma cell U251[J]. World Neurosurg, 2013, 80(3): 363
[30] Shen H, Yang Y, Xia S, et al. Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment[J]. Dis Esophagus, 2014, 27(7): 685

相似文献/References:

[1]袁华尊,孙保存,赵秀兰,等.Amotl2促进肝细胞肝癌血管生成拟态及EMT形成[J].天津医科大学学报,2016,22(04):277.
　YUAN Hua-zun,SUN Bao-cun,ZHAO Xiu-lan,et al.Amotl2 promotes vasculogenic mimicry and epithelial-mesenchymal transition in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2016,22(05):277.
[2]郑 鹏,李 强.BCLC-B期肝细胞肝癌治疗效果分析[J].天津医科大学学报,2016,22(05):421.
　ZHENG Peng,LI Qiang.Analysis of therapeutic effect on patients with BCLC -B hepatocellular carcinoma[J].Journal of Tianjin Medical University,2016,22(05):421.
[3]温鹏,韩玉娟,杨剑,等.肝细胞癌患者缩短普美显强化MRI检查中肝胆期时间的探索[J].天津医科大学学报,2022,28(04):433.
　WEN Peng,HAN Yu-juan,YANG Jian,et al.Exploration of shortening the duration of hepatobiliary phase in EOB enhanced MRI for patients with hepatocellular carcinoma[J].Journal of Tianjin Medical University,2022,28(05):433.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金面上项目（81572872）
作者简介 张宁（1992-），女，硕士在读，研究方向：病理学；
通信作者：刘铁菊，E-mail:liutieju@tmu.edu.cn。

常用功能

更新日期/Last Update: 2020-09-18